Cromolyn Sodium Oral Solution (concentrate)

Dosage for Cromolyn varies significantly based on the condition being treated and the route of administration.

• For Systemic Mastocytosis (Oral Solution): The typical initial dose for adults is 200 mg (two 5 mL ampules) taken four times daily. This should be taken approximately 30 minutes before meals and at bedtime. If symptoms are not controlled within 2-3 weeks, the dose may be increased, but should not exceed 40 mg/kg/day.
• For Chronic Asthma (Inhalation): The standard dose for nebulization is 20 mg (one ampule) inhaled four times daily at regular intervals. Some patients may be maintained on a lower dose of three times daily once symptoms are stabilized.
• For Allergic Rhinitis (Nasal Spray): One spray in each nostril 3 to 6 times daily. For best results, treatment should begin before the allergy season starts.
• For Allergic Conjunctivitis (Eye Drops): One or two drops in each eye 4 to 6 times daily.

Cromolyn is frequently used in pediatric populations due to its safety profile, but age restrictions apply:

• Systemic Mastocytosis (Oral): For children aged 2 to 12 years, the starting dose is 100 mg (one ampule) four times daily. For infants and children under 2, the dose is typically 20 mg/kg/day divided into four doses, but this requires strict medical supervision.
• Asthma (Inhalation): Approved for children 2 years of age and older at the same dose as adults (20 mg four times daily).
• Allergic Rhinitis (Nasal): Approved for children 2 years and older (one spray per nostril 3-6 times daily).
• Ophthalmic: Generally approved for children 4 years of age and older.

Renal Impairment

Because Cromolyn is excreted unchanged in the urine, patients with significant renal impairment (kidney disease) may require a reduced dose or increased monitoring. However, because systemic absorption is low, specific GFR-based adjustments are rarely standardized; clinical judgment is required.

Hepatic Impairment

Since the drug is also excreted via the bile, patients with severe hepatic (liver) dysfunction should be monitored closely, though no formal dose adjustment guidelines exist due to the lack of liver metabolism.

Elderly Patients

Clinical studies have not identified significant differences in response between elderly and younger patients. However, dose selection should be cautious, starting at the low end of the dosing range to account for the higher frequency of decreased organ function in this population.

• Oral Solution (Gastrocrom): Do not swallow the liquid directly from the ampule. Open the ampule and squeeze the liquid into a glass of water (not juice or milk). Stir well and drink the entire mixture immediately. Take this on an empty stomach, at least 30 minutes before eating.
• Inhalation Solution: Use only with a power-operated nebulizer equipped with a face mask or mouthpiece. Do not use a hand-held 'puffer' unless specifically prescribed in that format. Ensure the nebulizer is cleaned according to the manufacturer's instructions to prevent infection.
• Storage: Store all forms at room temperature (15°C to 30°C or 59°F to 86°F). Protect the oral and inhalation solutions from light. Do not use if the solution is discolored or contains precipitate (particles).

If you miss a dose of Cromolyn, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not double the dose to 'catch up,' as this may increase the risk of side effects.

Cromolyn is remarkably non-toxic due to its low absorption. In the event of an overdose, symptoms are likely to be limited to an exaggeration of common side effects, such as nausea or throat irritation. There is no specific antidote. Treatment involves supportive care and monitoring by a healthcare professional. If you suspect an overdose, contact your local poison control center or seek emergency medical attention immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Because Cromolyn is often applied locally (to the lungs, nose, or eyes), side effects are frequently localized to the site of administration. For the inhalation solution, the most common side effect is throat irritation or a cough immediately following the use of the nebulizer. This occurs because the mist can be slightly irritating to the sensitive lining of the airways. For the oral solution, some patients report a bitter taste or mild nausea during the first few days of treatment. These symptoms typically diminish as the body adjusts to the medication.

• Gastrointestinal: Diarrhea, abdominal pain, and flatulence (gas) may occur with the oral solution. Paradoxically, while Cromolyn treats these symptoms in mastocytosis, it can occasionally cause them as the gut microbiome or motility reacts to the drug.
• Respiratory: Nasal congestion, sneezing, or a 'stuffy' feeling after using the nasal spray.
• Dermatological: Mild skin rashes or itching (pruritus) have been reported.
• Neurological: Occasional headaches or dizziness, though these are rarely severe enough to warrant discontinuation of the drug.

• Musculoskeletal: Joint pain (arthralgia) and muscle aches (myalgia) have been documented in rare clinical cases.
• Urinary: Painful urination (dysuria) or increased frequency of urination.
• Psychiatric: Fatigue, irritability, or insomnia, though a direct causal link to Cromolyn is difficult to establish given its low systemic absorption.

> Warning: Stop taking Cromolyn and call your doctor immediately if you experience any of these.

• Anaphylaxis: While extremely rare, severe allergic reactions to Cromolyn can occur. Symptoms include hives, swelling of the face, lips, or tongue, severe dizziness, and difficulty breathing.
• Paradoxical Bronchospasm: In some asthma patients, inhaling the medication can cause an immediate tightening of the airways (bronchospasm) instead of preventing it. If you experience sudden wheezing or gasping for air after a dose, use your rescue inhaler and seek emergency care.
• Laryngeal Edema: Swelling of the throat that can obstruct breathing.
• Severe Skin Reactions: Erythema multiforme or Stevens-Johnson Syndrome (SJS) are theoretically possible with any medication, though they are exceptionally rare with Cromolyn.

Cromolyn is generally considered safe for long-term use, spanning years or even decades. Unlike inhaled corticosteroids, Cromolyn does not cause thinning of the skin, bone loss (osteoporosis), or suppression of the adrenal glands. There is no evidence that long-term use leads to tolerance (where the drug becomes less effective over time). However, patients on long-term therapy should have regular check-ups to ensure their underlying condition (like asthma) is still being managed effectively.

No FDA black box warnings for Cromolyn. It is considered one of the safest medications in the respiratory and allergy therapeutic classes. However, the lack of a black box warning does not mean the drug is without risk; it must be used strictly according to the prescribed guidelines.

Report any unusual symptoms to your healthcare provider. Clinical monitoring is essential to differentiate between drug side effects and the progression of the underlying disease state.

Cromolyn is a preventative medication and is NOT a rescue treatment. It will not stop an asthma attack or acute bronchospasm once it has started. Patients must always have a fast-acting bronchodilator (such as Albuterol) available for emergency use. Using Cromolyn during an active attack may actually worsen the condition by irritating the already constricted airways.

No FDA black box warnings for Cromolyn. The safety profile of this drug is well-established across pediatric, adult, and geriatric populations.

• Allergic Reactions: Patients with a known hypersensitivity to Cromolyn Sodium or any of the inactive ingredients in the formulation (such as benzalkonium chloride in some nasal sprays) must not use this medication. Anaphylaxis has been reported, though it is rare.
• Asthma Tapering: If a patient is switching from a corticosteroid to Cromolyn, the steroid dose must be tapered very slowly under a doctor's supervision. Suddenly stopping a steroid can lead to adrenal insufficiency or a severe rebound of asthma symptoms.
• Renal and Hepatic Function: While systemic absorption is low, the drug is cleared via the kidneys and liver. Patients with severe impairment in these organs should be monitored for potential accumulation, although this is clinically rare.
• Paradoxical Bronchospasm: As with any inhaled medication, there is a risk of acute bronchospasm. If this occurs, the medication should be discontinued immediately and alternative therapy established.

For most patients, routine laboratory monitoring (like blood tests) is not required for Cromolyn therapy. However, for those with systemic mastocytosis, healthcare providers may monitor:

• Tryptase Levels: To track the activity of mast cells.
• Pulmonary Function Tests (PFTs): For asthma patients, periodic spirometry is recommended to ensure the prophylactic treatment is effective.
• Kidney and Liver Function: Periodic baseline tests in patients with known pre-existing organ failure.

Cromolyn generally does not cause drowsiness or cognitive impairment. Most patients can safely drive or operate heavy machinery while taking this medication. However, if you experience dizziness or blurred vision (with eye drops), wait until these symptoms pass before engaging in tasks that require alertness.

There are no known direct interactions between Cromolyn and alcohol. However, alcohol can be a trigger for asthma and can worsen the flushing and gastrointestinal symptoms associated with systemic mastocytosis. Patients are advised to discuss their alcohol consumption with their doctor to ensure it does not interfere with the management of their underlying condition.

Do not stop taking Cromolyn abruptly without consulting your healthcare provider. Because it is a preventative drug, stopping it can lead to a return of symptoms within a few days. If discontinuation is necessary, your doctor will provide a plan to monitor for symptom flares.

> Important: Discuss all your medical conditions with your healthcare provider before starting Cromolyn.

There are currently no medications that are absolutely contraindicated for use with Cromolyn. Because of its unique mechanism of action and minimal systemic absorption, it does not typically interfere with the metabolic pathways of other drugs.

While no 'major' drug-drug interactions are listed in the official FDA labeling, caution should be exercised when using Cromolyn alongside other inhaled medications.

• Other Inhalants: When using multiple nebulized medications, there is a risk of physical incompatibility if they are mixed in the same nebulizer cup. For example, Cromolyn solution should generally not be mixed with other drugs unless specifically directed by a pharmacist, as the pH change could cause the drugs to precipitate (turn into solids), reducing their effectiveness and potentially damaging the nebulizer.

• Isoproterenol: Some older studies suggested that the combination of inhaled Cromolyn and isoproterenol (a bronchodilator) might increase the risk of heart palpitations in very sensitive individuals, though this is rarely seen with modern selective beta-agonists like Albuterol.
• Theophylline: While no direct chemical interaction exists, patients taking both drugs for asthma should have their theophylline levels monitored closely, as the addition of Cromolyn may allow for a reduction in the theophylline dose.

• Empty Stomach Requirement: For the oral solution (Gastrocrom), food significantly interferes with the drug's ability to coat the intestinal mast cells. It must be taken 30 minutes before meals. Taking it with high-fat meals can reduce the already low absorption even further.
• Dairy and Juice: Do not mix oral Cromolyn with milk, fruit juice, or soda. These substances can alter the pH and stability of the drug. Use only plain water for dilution.

• Quercetin: This natural supplement also has mast cell stabilizing properties. Taking it with Cromolyn might have an additive effect, though this has not been clinically studied. Consult a doctor before combining them.
• St. John's Wort: Unlike many other drugs, Cromolyn is not metabolized by the CYP3A4 enzyme, so St. John's Wort does not reduce its efficacy.

Cromolyn does not typically interfere with standard blood chemistry, hematology, or urinalysis tests. It does not affect blood glucose levels or cholesterol panels. However, always inform your laboratory technician of all medications you are taking.

For each major interaction, the primary concern is not toxicity, but rather the loss of therapeutic efficacy due to improper administration or physical incompatibility of the solution. Management involves separating doses and ensuring the oral form is taken on an empty stomach.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Cromolyn is contraindicated in the following circumstances:

1. 1Hypersensitivity: Any patient with a documented history of severe allergic reaction (anaphylaxis, angioedema) to Cromolyn Sodium must never use any form of the medication. The mechanism involves an overreaction of the immune system to the drug molecule itself.
2. 2Acute Asthma Attack: Cromolyn is absolutely contraindicated as a primary treatment for status asthmaticus or acute bronchospasm. Because it takes weeks to reach full effect and has no bronchodilatory action, using it during an emergency can be fatal if it replaces life-saving rescue medications.

Conditions requiring careful risk-benefit analysis include:

• Severe Renal Impairment: While not an absolute contraindication, the risk of systemic accumulation is higher. Doctors may choose alternative treatments if the patient's GFR is significantly low.
• Severe Hepatic Impairment: Similar to renal issues, the biliary excretion route may be compromised, requiring closer clinical monitoring.
• Coronary Artery Disease or Cardiac Arrhythmias: In rare cases, the stress of the inhalation process or the drug itself has been associated with minor cardiac changes. Patients with unstable heart conditions should be monitored during the initiation of therapy.

There is no known cross-sensitivity between Cromolyn and other common drug classes like penicillins, sulfonamides, or NSAIDs. It is chemically distinct from corticosteroids and antihistamines. However, patients sensitive to preservatives like benzalkonium chloride or EDTA should check the inactive ingredients of the specific brand of nasal spray or eye drops they are using, as these can cause localized irritation.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Cromolyn.

Cromolyn is classified as FDA Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, and there are no adequate and well-controlled studies in pregnant women. Because Cromolyn has extremely low systemic absorption, it is often considered one of the preferred preventative treatments for asthma and allergies during pregnancy when non-pharmacological measures are insufficient. However, it should only be used if clearly needed and prescribed by a physician who has weighed the risks of the medication against the risks of uncontrolled asthma (which can cause fetal hypoxia).

It is not known whether Cromolyn is excreted in human milk. However, because the systemic levels of the drug in the mother's blood are negligible after inhalation, nasal, or oral administration, the amount that could potentially reach a nursing infant is thought to be extremely low. The American Academy of Pediatrics considers Cromolyn to be generally compatible with breastfeeding. As a precaution, monitor the infant for any unusual signs, such as changes in feeding or sleeping patterns.

Cromolyn has a long history of safe use in children. It is FDA-approved for the treatment of asthma in children as young as 2 years old and for systemic mastocytosis in infants (under strict guidance). Unlike inhaled steroids, it does not carry the risk of growth suppression in children. This makes it a valuable 'steroid-sparing' agent in pediatric respiratory medicine. Parents should ensure that children use the nebulizer correctly to ensure the medication reaches the lower airways.

In patients over 65, Cromolyn remains a safe option due to its lack of sedative effects and minimal drug interactions. The primary concern in the elderly is the physical ability to use a nebulizer or nasal spray correctly. Additionally, elderly patients are more likely to have reduced renal or hepatic clearance; while this rarely requires a dose change for Cromolyn, it should be kept in mind if the patient has multi-organ dysfunction.

In patients with kidney disease, the half-life of the small absorbed fraction of Cromolyn may be prolonged. While the drug is not known to be nephrotoxic (harmful to the kidneys), a dose reduction may be considered in patients with a GFR below 30 mL/min to prevent any theoretical systemic buildup.

There are no specific guidelines for Cromolyn use in patients with liver cirrhosis or hepatitis. However, since biliary excretion is a major pathway for the drug, patients with Child-Pugh Class C impairment should be monitored for signs of increased systemic side effects.

> Important: Special populations require individualized medical assessment.

Cromolyn Sodium is a mast cell stabilizer. Its primary molecular mechanism involves the inhibition of the release of mediators from mast cells. It is believed to act on the exterior of the cell membrane to prevent the opening of calcium channels. By preventing the influx of calcium ions ($Ca^{2+}$) into the mast cell, Cromolyn inhibits the degranulation process. This prevents the release of histamine, leukotrienes (specifically LTC4, LTD4, and LTE4), and other inflammatory cytokines. It also inhibits the activation of other inflammatory cells such as eosinophils and neutrophils, which play a role in the late-phase allergic response.

Cromolyn has a slow onset of action for chronic conditions. While some effect on exercise-induced asthma can be seen within 15-30 minutes of inhalation, the full therapeutic benefit for chronic asthma or mastocytosis often takes 2 to 4 weeks of consistent dosing. It does not exhibit a traditional dose-response curve in the same way bronchodilators do; rather, it works by maintaining a 'steady state' of mast cell stability. Tolerance does not develop with prolonged use.

| Parameter | Value |

|---|---|

| Bioavailability | <1% (Oral), 8-10% (Inhalation) |

| Protein Binding | 65% - 75% |

| Half-life | 80 - 90 minutes |

| Tmax | 15 minutes (Inhalation) |

| Metabolism | None (Excreted unchanged) |

| Excretion | Renal 50%, Biliary 50% |

• Molecular Formula: $C_{23}H_{14}Na_{2}O_{11}$
• Molecular Weight: 512.3 g/mol
• Solubility: Soluble in water (up to 5%); insoluble in alcohol.
• Structure: It is the disodium salt of 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane. It consists of two chromone rings linked by a flexible chain.

Cromolyn is the prototype of the Mast Cell Stabilizer class. Other drugs in this general therapeutic area include Nedocromil and certain antihistamines with mast cell stabilizing properties (like Ketotifen and Olopatadine). However, Cromolyn remains the most widely used pure stabilizer for systemic and respiratory applications.